Table 1.
Demographics for samples 1 and 2
| CON (n = 31) Sample 1 | SCZ (n = 28) Sample 1 | SCZ (n = 23) Sample 2 | F/t/Χ 2 Statistica | |
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 31.06 (7.87) | 33.17 (6.64) | 24.56 (3.58) | 11.82*** |
| Gender (% male) | 51.61 | 64.29 | 69.57 | 0.97 |
| Parental SES, yearsb | 30.25 (9.32) | 23.15 (9.87) | 26.75 (8.62) | 4.32* |
| Duration of Illness, yearsc | – | 14.57 (6.34) | 5.47 (3.10) | 6.04*** |
| CPZeq, mg | – | 329.79 (207.31) | – | – |
| Medicationd | ||||
| % Typical only | – | 85.71 | 73.91 | |
| % Atypical only | – | 0.00 | 0.00 | 1.83 |
| % Both | – | 14.29 | 21.74 | |
| % Neither | – | 0.00 | 4.35 | |
| Clinical symptom domainse | ||||
| Experiential negative | – | 3.02 (1.29) | 2.72 (1.03) | 0.91 |
| Expressive negative | – | 2.69 (1.26) | 1.52 (1.16) | 3.43** |
| Total symptom severity | – | 2.11 (1.42) | 1.55 (0.97) | 1.60 |
| Race | ||||
| % Caucasian | 51.61 | 42.86 | 65.22 | 5.35 |
| % African American | 32.26 | 39.29 | 34.78 | |
| % Other | 16.13 | 17.86 | 0.00 | |
| Cognitive function | ||||
| Global Cognitionf | 0.04 (0.62) | −0.89 (0.58) | −1.02 (0.61) | 26.20*** |
| Cognitive empathy task | ||||
| Accuracy | 0.86 (0.06) | 0.73 (0.10) | – | 5.87*** |
| Reaction time (sec) | 1.40 (0.26) | 1.57 (0.31) | – | −2.22* |
| Inter‐component connectivity | ||||
| M‐T Metric | 0.31 (0.22) | 0.29 (0.17) | 0.31 (0.20) | 0.09 |
| O‐T Metric | 0.22 (0.18) | 0.23 (0.14) | 0.15 (0.14) | 2.16 |
| M‐O Metric | 0.36 (0.17) | 0.35 (0.19) | 0.28 (0.14) | 1.62 |
ANOVA was used when all three groups had data for a demographic variable; t‐tests were used when only two groups had data for a demographic variable.
Completed by n = 30 CON Sample 1 and n = 27 SCZ Sample 1.
Completed by n = 21 SCZ Sample 2.
CPZeq data was not available for Sample 2.
Symptom domain scores were obtained by summing the average global ratings for the respective domain, and dividing by the number of global ratings included.
Cognitive subtests were transformed to z‐scores using control data from the respective site.
P < 0.10, * P < 0.05, ** P < 0.01, *** P < 0.001.
Abbreviations: CON, control subjects; SCZ, schizophrenia subjects; CPZeq, chlorpromazine equivalents; M, medial prefrontal and anterior cingulate cortex component; T, superior temporal gyrus, temporo‐parietal junction, and temporal poles component; O, orbitofrontal cortex component.